75TiP Open-label, phase II study of tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and with pembrolizumab + platinum-based chemotherapy +/− pemetrexed in pati... von Paz-Ares, L., Parakh, S., Park, J., Rojas, C., Orlandi, F., Veillon, R., Isambert, N., Nagy, T., Muller, V., Medgyasszay, B., Rodriguez-Abreu, D., Fernandez, A., Puaud, A., Bensfia, S., Yang, N., Spira, A.

Volltext

6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up von Rodriguez Abreu, D., Reck, M., Şendur, N., Park, K., Lee, D.H., Cicin, I., Yumuk, P.F., Orlandi, F.J., Leal, T.A., Soparattanapaisarn, N., Langleben, A., Califano, R., Medgyasszay, B., Hsia, T-C., Otterson, G.A., Woods, T., Jensen, E., Samkari, A., Boyer, M.

Volltext

97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 von Robinson, A.G., Vicente, D., Tafreshi, A., Parra, H. Soto, Mazieres, J., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Halmos, B., Liu, C-C., Schwarzenberger, P., Piperdi, B., Paz-Ares, L.

Volltext

PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598 von Boyer, M., Sendur, M.A.N., Rodríguez-Abreu, D., Park, K., Lee, D.H., Cicin, I., Yumuk, P.F., Orlandi, F., Leal, T., Molinier, O., Soparattanapaisam, N., Langleben, A., Califano, R., Medgyasszay, B., Hsia, T., Otterson, G., Xu, L., Piperdi, B., Samkari, A., Reck, M.

Volltext

OA03.08 Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression von Purkalne, G., Ferrarotto, R., Anderson, I., Medgyasszay, B., García-Campelo, M.R., Edenfield, W., Feinstein, T., Johnson, J., Kalmadi, S., Lammers, P., Hernandez, A.S., Pritchett, Y., Malik, R.K., Morris, S.R., Csőszi, T.

Volltext

Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 von Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Beatrix, B., Rodríguez Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Bas, T., Piperdi, B., Halmos, B.

Volltext

LBA82Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 von Paz-Ares, L, Vicente, D, Tafreshi, A, Robinson, A, Soto Parra, H, Mazières, J, Hermes, B, Cicin, I, Medgyasszay, B, Beatrix, B, Rodríguez Cid, J, Okamoto, I, Lee, S, Ramlau, R, Vladimirov, V, Cheng, Y, Deng, X, Bas, T, Piperdi, B, Halmos, B

Volltext

LBA82 - Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 von Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Beatrix, B., Rodríguez Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Bas, T., Piperdi, B., Halmos, B.

Volltext

Benralizumab for the Prevention of COPD Exacerbations von Criner, Gerard J, Celli, Bartolome R, Brightling, Christopher E, Agusti, Alvar, Papi, Alberto, Singh, Dave, Sin, Don D, Vogelmeier, Claus F, Sciurba, Frank C, Bafadhel, Mona, Backer, Vibeke, Kato, Motokazu, Ramírez-Venegas, Alejandra, Wei, Yu-Feng, Bjermer, Leif, Shih, Vivian H, Jison, Maria, O’Quinn, Sean, Makulova, Natalya, Newbold, Paul, Goldman, Mitchell, Martin, Ubaldo J

Volltext

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study von Maher, Toby M, Stowasser, Susanne, Nishioka, Yasuhiko, White, Eric S, Cottin, Vincent, Noth, Imre, Selman, Moisés, Rohr, Klaus B, Michael, Andreas, Ittrich, Carina, Diefenbach, Claudia, Jenkins, R Gisli, Glaspole, Ian, Holmes, Mark, Troy, Lauren, Bondue, Benjamin, Dahlqvist, Caroline, Louis, Renaud, Van Meerbeeck, Jan, Wuyts, Wim, Bittenglova, Radka, Kolek, Vitezslav, Pauk, Norbert, Reiterer, Pavel, Sterclova, Martina, Mäkitaro, Riitta, Myllärniemi, Marjukka, Purokivi, Minna, Rantala, Terhi, Cottin, Vincent, Couturaud, Francis, Israel-Biet, Dominique, Jouneau, Stéphane, Kessler, Romain, Lebargy, François, Marchand-Adam, Sylvain, Bollmann, Tom, Günther, Andreas, Hammerl, Peter, Kirschner, Joachim, Kirsten, Anne-Marie, Kreuter, Michael, Neurohr, Claus, Prasse, Antje, Schönfeld, Nicolas, Wiewrodt, Rainer, Attila, Somfay, Balazs, Medgyasszay, Csanky, Eszter, Losonczy, György, Hayashi, Hiroki, Homma, Sakae, Inoue, Yoshikazu, Izumi, Shinyu, Kitamura, Hideya, Nishioka, Yasuhiko, Nishiyama, Osamu, Ogura, Takashi, Okamoto, Masaki, Saito, Takefumi, Taniguchi, Hiroyuki, Zaizen, Yoshiaki, Filipowska, Marzena, Jarzemska, Agnieszka, Pierzchala, Wladyslaw, Piotrowski, Wojciech, Sladek, Krzysztof, Trawinska, Ewa, Kim, Young Whan, Park, Jong Sun, Song, Jin Woo, Aburto, Myriam, Castillo Villegas, Diego, Echave-Sustaeta, José María, Garcia Fadul, Christian, Herrera, Susana, Moises, Jorge, Molina-Molina, María, Moreno, Amalia, Nieto, Asunción, Rodríguez Nieto, María Jesús, Rodriguez-Portal, José Antonio, Safont, Belen, Sellares, Jacobo, Valenzuela, Claudia, Adamali, Huzaifa, Chaudhuri, Nazia, Gibbons, Michael, Hoyles, Rachel, Maher, Toby, Parfrey, Helen, Averill, Francis, Chambers, Steven, Ettinger, Neil, Giessel, Glenn, Jones, Lisa M, Kaye, Mitchell G, Oelberg, David, Westerman, Jan H, Zoz, Donald

Volltext